Exelixis (NASDAQ:EXEL) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday.
A number of other equities analysts also recently weighed in on EXEL. BidaskClub downgraded shares of Exelixis from a “buy” rating to a “hold” rating in a report on Thursday, March 1st. Cann reaffirmed a “buy” rating and set a $40.00 price objective on shares of Exelixis in a research report on Thursday, March 8th. Zacks Investment Research cut shares of Exelixis from a “hold” rating to a “sell” rating in a research report on Tuesday, March 13th. TheStreet cut shares of Exelixis from a “b” rating to a “c+” rating in a research report on Thursday, March 15th. Finally, William Blair reaffirmed a “buy” rating on shares of Exelixis in a research report on Wednesday, April 11th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $32.80.
Shares of EXEL stock opened at $21.52 on Thursday. The company has a market cap of $6.24 billion, a price-to-earnings ratio of 42.20 and a beta of 2.12. Exelixis has a 52 week low of $18.50 and a 52 week high of $32.50.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.21. Exelixis had a net margin of 43.39% and a return on equity of 77.39%. The company had revenue of $212.35 million for the quarter, compared to the consensus estimate of $146.39 million. equities analysts anticipate that Exelixis will post 0.85 earnings per share for the current fiscal year.
In other Exelixis news, CMO Gisela Schwab sold 22,500 shares of the business’s stock in a transaction dated Thursday, May 3rd. The stock was sold at an average price of $23.09, for a total transaction of $519,525.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Michael Morrissey sold 90,000 shares of the business’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $19.62, for a total value of $1,765,800.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 588,023 shares of company stock valued at $12,255,688. 4.80% of the stock is owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of EXEL. TLP Group LLC acquired a new position in shares of Exelixis in the first quarter valued at approximately $179,000. American International Group Inc. acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $208,000. Massachusetts Financial Services Co. MA acquired a new position in shares of Exelixis in the first quarter valued at approximately $215,000. Meeder Asset Management Inc. increased its stake in shares of Exelixis by 83.4% in the first quarter. Meeder Asset Management Inc. now owns 9,887 shares of the biotechnology company’s stock valued at $218,000 after buying an additional 4,495 shares during the period. Finally, Globeflex Capital L P acquired a new position in shares of Exelixis in the fourth quarter valued at approximately $246,000. 77.81% of the stock is owned by hedge funds and other institutional investors.
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.